• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PGL
Click for more information
0.00% 85.0¢

PROSPA GROUP LIMITED. - Announcements

Currently unlisted. Proposed listing date: APPLICATION WITHDRAWN watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PGLChange of Director's Interest Notice22/05/13
PGLRights Issue - Notice under Section 708A(5)(e)22/05/13
PGLRights Issue - Share Allotment22/05/13
PGLRights Issue - Notification of Subscriptions20/05/13
PGLDispatch of Non-Renounceable Rights Issue Offer Document01/05/13
PGLRights Issue - Notice to Ineligible Shareholders18/04/13
PGLRights Issue - Notice to Eligible Shareholders18/04/13
PGLRights Issue - Letter to Option Holders17/04/13
PGLRights Issue - Notice Under Section 708AA17/04/13
PGLOffer Document - Non-Renounceable Rights IssuePRICE SENSITIVE17/04/13
PGLAppendix 3B - Non Renounceable Pro Rata Rights Issue16/04/13
PGLNon Renounceable Pro Rata Rights IssuePRICE SENSITIVE16/04/13
PGLChange of Director's Interest Notice27/03/13
PGLChange of Director's Interest Notice22/03/13
PGLChange of Director's Interest Notice15/03/13
PGLProgen Pharmaceuticals signs PG545 LicensePRICE SENSITIVE01/03/13
PGLHalf Yearly Report and AccountsPRICE SENSITIVE28/02/13
PGLReceipt of R&D Tax Incentive RefundPRICE SENSITIVE31/01/13
PGLQueensland Storm - Operations Unaffected31/01/13
PGLR&D Tax Incentive RefundPRICE SENSITIVE14/01/13
PGLProgen Pharmaceuticals Ltd signs Binding License Term SheetPRICE SENSITIVE28/12/12
PGLAppendix 3Y17/12/12
PGLAppendix 3Y06/12/12
PGL2012 Form 20-F Filed with the US SEC04/12/12
PGLResults of Meeting29/11/12
PGLAGM Capital Raising PresentationPRICE SENSITIVE29/11/12
PGLChairman's Address to Shareholders29/11/12
PGLNotice of Annual General Meeting/Proxy Form25/10/12
PGLPI-88 Phase II Melanoma Clinical Study ResultsPRICE SENSITIVE17/10/12
PGLCompany Secretary Resignation12/10/12
PGLChange of Director's Interest Notice01/10/12
PGLAnnual Report to shareholders28/09/12
PGLPI-88 Phase III UpdatePRICE SENSITIVE27/09/12
PGLAppendix 3Y25/09/12
PGLPG545 UpdatePRICE SENSITIVE21/09/12
PGLAppendix 3Y12/09/12
PGLPreliminary Final ReportPRICE SENSITIVE31/08/12
PGLCompany Secretary Appointment21/08/12
PGLProgen Pharmaceuticals Granted Additional US PatentPRICE SENSITIVE17/07/12
PGLProgen Pharmaceuticals Granted Australian PatentPRICE SENSITIVE30/05/12
PGLProgen Presents PG545 at AACR Meeting in ChicagoPRICE SENSITIVE04/04/12
PGLHalf Yearly Report and AccountsPRICE SENSITIVE28/02/12
PGLProgen Licensee Receives IND Approval in China for PI-88PRICE SENSITIVE31/01/12
PGLAppendix 3Y03/01/12
PGLPG545 UpdatePRICE SENSITIVE21/12/11
PGLChange of Director's Interest Notice05/12/11
PGLResults of Meeting30/11/11
PGLChairman's Address - 2011 AGM30/11/11
PGL2011 Form 20-F Filed with US SEC30/11/11
PGLProgen Presents PG545 at AACR Cancer Conference14/11/11
PGLNotice of Annual General Meeting/Proxy Form31/10/11
PGLAppendix 3Y25/10/11
PGLProgen Licensee Receives IND Approval in Korea for PI-88PRICE SENSITIVE17/10/11
PGLNon-Executive Director Resignation30/09/11
PGLAnnual Report to shareholders30/09/11
PGLAppendix 3Y29/09/11
PGLLicensee Commences Recruitment, End of Settlement AgreementPRICE SENSITIVE26/09/11
PGLClosure of PG545 Phase 1a Clinical TrialPRICE SENSITIVE20/09/11
PGLAppendix 3Z24/08/11
PGLAppendix 3Z24/08/11
PGLPreliminary Final ReportPRICE SENSITIVE23/08/11
PGL +Progen Subsidiary Secures New Manufacturing ContractsPRICE SENSITIVE20/07/11
PGLPI-88 Receives Orphan Medicinal Product DesignationPRICE SENSITIVE29/06/11
PGLPI-88 Phase III UpdatePRICE SENSITIVE23/06/11
PGLAppendix 3X - Woei-Jia Jiang21/06/11
PGLAppendix 3Z - Paul Lin21/06/11
PGLProgen Board and Senior Management ChangesPRICE SENSITIVE16/06/11
PGLCompletes Epi Pharmaceuticals Inc Formation and Reduces RiskPRICE SENSITIVE19/05/11
PGLDiversity Policy16/05/11
PGLProgen Licensee Gains Approval for Phase III Clinical TrialPRICE SENSITIVE19/04/11
PGLProgen's PG11047 Clinical Study Completes EnrolmentPRICE SENSITIVE06/04/11
PGLPG545 Presented at the AACR Annual MeetingPRICE SENSITIVE05/04/11
PGLProgen Enters Diabetes Collaboration with ANUPRICE SENSITIVE30/03/11
PGLWholesale Investor Presentation28/03/11
PGLCompany Newsletter23/03/11
AAX +Change of Share Registry Address07/03/11
PGLBoardroom Radio Australia Interviews CEO Sue MacLeman23/02/11
PGLCorporate Presentation Q1 201121/02/11
PGLHalf Yearly Report and AccountsPRICE SENSITIVE16/02/11
PGLProgen Presents PG545 Data at Lorne Cancer Conference11/02/11
PGLPG545 Data Published in British Journal of CancerPRICE SENSITIVE03/02/11
PGLProgen Pharmaceuticals Granted US PatentPRICE SENSITIVE25/01/11
PGLBrisbane Flood Update17/01/11
PGLJP Morgan Conference Presentation12/01/11
PGLAppendix 3B07/01/11
PGLAppendix 3B07/01/11
PGLTrading Policy31/12/10
PGL2010 Form 20-F Filed with US SEC24/12/10
PGLResults of Meeting16/11/10
PGLCEO's Address to Shareholders - 2010 AGM16/11/10
PGLChairman's Address to Shareholders - 2010 AGM16/11/10
PGLPG545 to Enter Clinic in First In-Human Cancer TrialPRICE SENSITIVE15/11/10
PGLProgen Receives Purchase Order for PI-88 Trial MaterialPRICE SENSITIVE12/11/10
PGLProgen Closes US Office and Continues to Drive Strategy29/10/10
PGLProgen presents at Life Science Investment Summit19/10/10
PGLProgen Presents PG545 at TRX10 Conference12/10/10
PGLNotice of Annual General Meeting/Proxy Form08/10/10
PGLAnnual Report to shareholders30/09/10
PGLProgen Presents at Rodman and Renshaw Investor Conference15/09/10
PGLPublication on PG1104714/09/10
PGLChange of Director's Interest Notice
22/05/13
PGLRights Issue - Notice under Section 708A(5)(e)
22/05/13
PGLRights Issue - Share Allotment
22/05/13
PGLRights Issue - Notification of Subscriptions
20/05/13
PGLDispatch of Non-Renounceable Rights Issue Offer Document
01/05/13
PGLRights Issue - Notice to Ineligible Shareholders
18/04/13
PGLRights Issue - Notice to Eligible Shareholders
18/04/13
PGLRights Issue - Letter to Option Holders
17/04/13
PGLRights Issue - Notice Under Section 708AA
17/04/13
PGLOffer Document - Non-Renounceable Rights Issue
17/04/13PRICE SENSITIVE
PGLAppendix 3B - Non Renounceable Pro Rata Rights Issue
16/04/13
PGLNon Renounceable Pro Rata Rights Issue
16/04/13PRICE SENSITIVE
PGLChange of Director's Interest Notice
27/03/13
PGLChange of Director's Interest Notice
22/03/13
PGLChange of Director's Interest Notice
15/03/13
PGLProgen Pharmaceuticals signs PG545 License
01/03/13PRICE SENSITIVE
PGLHalf Yearly Report and Accounts
28/02/13PRICE SENSITIVE
PGLReceipt of R&D Tax Incentive Refund
31/01/13PRICE SENSITIVE
PGLQueensland Storm - Operations Unaffected
31/01/13
PGLR&D Tax Incentive Refund
14/01/13PRICE SENSITIVE
PGLProgen Pharmaceuticals Ltd signs Binding License Term Sheet
28/12/12PRICE SENSITIVE
PGLAppendix 3Y
17/12/12
PGLAppendix 3Y
06/12/12
PGL2012 Form 20-F Filed with the US SEC
04/12/12
PGLResults of Meeting
29/11/12
PGLAGM Capital Raising Presentation
29/11/12PRICE SENSITIVE
PGLChairman's Address to Shareholders
29/11/12
PGLNotice of Annual General Meeting/Proxy Form
25/10/12
PGLPI-88 Phase II Melanoma Clinical Study Results
17/10/12PRICE SENSITIVE
PGLCompany Secretary Resignation
12/10/12
PGLChange of Director's Interest Notice
01/10/12
PGLAnnual Report to shareholders
28/09/12
PGLPI-88 Phase III Update
27/09/12PRICE SENSITIVE
PGLAppendix 3Y
25/09/12
PGLPG545 Update
21/09/12PRICE SENSITIVE
PGLAppendix 3Y
12/09/12
PGLPreliminary Final Report
31/08/12PRICE SENSITIVE
PGLCompany Secretary Appointment
21/08/12
PGLProgen Pharmaceuticals Granted Additional US Patent
17/07/12PRICE SENSITIVE
PGLProgen Pharmaceuticals Granted Australian Patent
30/05/12PRICE SENSITIVE
PGLProgen Presents PG545 at AACR Meeting in Chicago
04/04/12PRICE SENSITIVE
PGLHalf Yearly Report and Accounts
28/02/12PRICE SENSITIVE
PGLProgen Licensee Receives IND Approval in China for PI-88
31/01/12PRICE SENSITIVE
PGLAppendix 3Y
03/01/12
PGLPG545 Update
21/12/11PRICE SENSITIVE
PGLChange of Director's Interest Notice
05/12/11
PGLResults of Meeting
30/11/11
PGLChairman's Address - 2011 AGM
30/11/11
PGL2011 Form 20-F Filed with US SEC
30/11/11
PGLProgen Presents PG545 at AACR Cancer Conference
14/11/11
PGLNotice of Annual General Meeting/Proxy Form
31/10/11
PGLAppendix 3Y
25/10/11
PGLProgen Licensee Receives IND Approval in Korea for PI-88
17/10/11PRICE SENSITIVE
PGLNon-Executive Director Resignation
30/09/11
PGLAnnual Report to shareholders
30/09/11
PGLAppendix 3Y
29/09/11
PGLLicensee Commences Recruitment, End of Settlement Agreement
26/09/11PRICE SENSITIVE
PGLClosure of PG545 Phase 1a Clinical Trial
20/09/11PRICE SENSITIVE
PGLAppendix 3Z
24/08/11
PGLAppendix 3Z
24/08/11
PGLPreliminary Final Report
23/08/11PRICE SENSITIVE
PGL +Progen Subsidiary Secures New Manufacturing Contracts
20/07/11PRICE SENSITIVE
PGLPI-88 Receives Orphan Medicinal Product Designation
29/06/11PRICE SENSITIVE
PGLPI-88 Phase III Update
23/06/11PRICE SENSITIVE
PGLAppendix 3X - Woei-Jia Jiang
21/06/11
PGLAppendix 3Z - Paul Lin
21/06/11
PGLProgen Board and Senior Management Changes
16/06/11PRICE SENSITIVE
PGLCompletes Epi Pharmaceuticals Inc Formation and Reduces Risk
19/05/11PRICE SENSITIVE
PGLDiversity Policy
16/05/11
PGLProgen Licensee Gains Approval for Phase III Clinical Trial
19/04/11PRICE SENSITIVE
PGLProgen's PG11047 Clinical Study Completes Enrolment
06/04/11PRICE SENSITIVE
PGLPG545 Presented at the AACR Annual Meeting
05/04/11PRICE SENSITIVE
PGLProgen Enters Diabetes Collaboration with ANU
30/03/11PRICE SENSITIVE
PGLWholesale Investor Presentation
28/03/11
PGLCompany Newsletter
23/03/11
AAX +Change of Share Registry Address
07/03/11
PGLBoardroom Radio Australia Interviews CEO Sue MacLeman
23/02/11
PGLCorporate Presentation Q1 2011
21/02/11
PGLHalf Yearly Report and Accounts
16/02/11PRICE SENSITIVE
PGLProgen Presents PG545 Data at Lorne Cancer Conference
11/02/11
PGLPG545 Data Published in British Journal of Cancer
03/02/11PRICE SENSITIVE
PGLProgen Pharmaceuticals Granted US Patent
25/01/11PRICE SENSITIVE
PGLBrisbane Flood Update
17/01/11
PGLJP Morgan Conference Presentation
12/01/11
PGLAppendix 3B
07/01/11
PGLAppendix 3B
07/01/11
PGLTrading Policy
31/12/10
PGL2010 Form 20-F Filed with US SEC
24/12/10
PGLResults of Meeting
16/11/10
PGLCEO's Address to Shareholders - 2010 AGM
16/11/10
PGLChairman's Address to Shareholders - 2010 AGM
16/11/10
PGLPG545 to Enter Clinic in First In-Human Cancer Trial
15/11/10PRICE SENSITIVE
PGLProgen Receives Purchase Order for PI-88 Trial Material
12/11/10PRICE SENSITIVE
PGLProgen Closes US Office and Continues to Drive Strategy
29/10/10
PGLProgen presents at Life Science Investment Summit
19/10/10
PGLProgen Presents PG545 at TRX10 Conference
12/10/10
PGLNotice of Annual General Meeting/Proxy Form
08/10/10
PGLAnnual Report to shareholders
30/09/10
PGLProgen Presents at Rodman and Renshaw Investor Conference
15/09/10
PGLPublication on PG11047
14/09/10
refresh Created with Sketch. REFRESH
 

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.